Tier 4 — mechanistic

Exploring the Molecular Mechanisms of Fisetin in Treating Periodontitis Through Multiomics and Network Pharmacology

Ma L, Zhang H, Liu Y, Liu Y, Zhou J, Yang H, Xu B
International Dental Journal 2025 Volume 75, issue 3, pages 2204-2221

Bibliography

PubMed
PMID 39755534
PubMed Central
PMC12142780
DOI
10.1016/j.identj.2024.12.012
Funding
Yunnan Provincial Department of Science and Technology and Kunming Medical University Joint Key Project (grant no. 202401AY070001-049).
Competing interests
No conflicts of interest were declared in the manuscript.

Study snapshot

DesignNetwork pharmacology target prediction, single-cell and spatial transcriptomic analysis of periodontitis tissue, a rat ligature-induced periodontitis model treated with oral fisetin, and an in vitro H2O2-induced oxidative stress model in human periodontal ligament fibroblasts (PDLFs).
ModelSprague-Dawley rats with ligature-induced periodontitis; human periodontal ligament fibroblasts (PDLFs) under H2O2-induced oxidative stress; single-cell RNA-seq analysis across 9 public datasets (32,984 cells).
SampleNetwork pharmacology identified 81 overlapping fisetin-periodontitis targets; rat model group sizes not fully specified in the extracted text; single-cell analysis pooled 32,984 cells from 9 datasets.
InterventionOral gavage fisetin at 20 mg/kg (low dose) or 100 mg/kg (high dose) every 2 days for 6 weeks in the rat ligature-induced periodontitis model; fisetin pre-treatment in H2O2-stressed PDLFs in vitro.
Duration6 weeks of oral dosing in the rat model; acute exposure in the in vitro fibroblast experiments.
EndpointsAlveolar bone loss (ABC-CEJ distance); Serum malondialdehyde (MDA) and superoxide dismutase (SOD); Single-cell target expression by cell type (fibroblasts, pericytes); Reactive oxygen species (ROS) accumulation, HO-1/GPX-4 antioxidant enzyme expression, apoptosis and proliferation in periodontal ligament fibroblasts

What the study showed, in plain terms

This is a mechanistic study of fisetin for gum disease (periodontitis), combining computer-based target prediction, single-cell gene analysis, a rat model of periodontitis, and lab experiments on human gum ligament cells. It is not a clinical trial in people with gum disease.

The computational analysis identified 81 molecular targets shared between fisetin and periodontitis biology, clustering around two protein families (EGFR/ALK/AXL and the MMP matrix metalloproteinase family), and single-cell sequencing showed these targets are mainly active in fibroblasts and pericytes — the connective-tissue and blood-vessel-supporting cells of the gums.

In rats with ligature-induced periodontitis (a standard lab model of gum disease), oral fisetin at both a low and a high dose significantly reduced the amount of bone lost around the teeth, and reduced markers of oxidative stress in the blood. In human gum ligament cells stressed with hydrogen peroxide in a dish, fisetin reduced oxidative damage, boosted the cells' own antioxidant defences, reduced cell death and supported cell survival.

The overall picture is a plausible antioxidant mechanism for fisetin in gum disease, built from strong preclinical building blocks (network pharmacology, single-cell data, an animal model and human cell culture) but with no human periodontitis trial yet. The authors themselves frame this as groundwork for future clinical trials, not as evidence fisetin treats gum disease in people today.

Key findings

  • Network pharmacology analysis identified 81 targets shared between fisetin and periodontitis pathways, with two dominant molecular clusters: the EGFR/ALK/AXL receptor family and the MMP (matrix metalloproteinase) family.
  • Single-cell RNA-seq across 32,984 cells from 9 periodontitis datasets showed these fisetin targets were primarily expressed in fibroblasts and pericytes rather than immune or epithelial cells.
  • In the rat ligature-induced periodontitis model, oral fisetin significantly reduced alveolar bone loss (ABC-CEJ distance) at both the 20 mg/kg low dose (p<0.0001) and 100 mg/kg high dose (p<0.001) compared with the untreated periodontitis model group.
  • Fisetin treatment significantly reduced serum malondialdehyde and restored superoxide dismutase activity in the rat model, indicating a systemic reduction in oxidative stress.
  • In H2O2-stressed human periodontal ligament fibroblasts, fisetin reduced reactive oxygen species accumulation, upregulated the antioxidant enzymes HO-1 and GPX-4, reduced apoptosis, and promoted cell proliferation.

What this study can and cannot tell us

This is entirely preclinical work — computational target prediction, a rat model, and in vitro human cell culture. There is no human periodontitis clinical trial evidence for fisetin, and the rat oral doses (20 and 100 mg/kg) have not been translated to a human-equivalent dose or tested for periodontal-specific safety.

Network pharmacology target-prediction methods (SwissTargetPrediction, ChemMapper, GeneCards, OMIM, DisGeNET) are hypothesis-generating computational tools; overlapping targets do not by themselves prove a causal mechanism, and the wet-lab validation in this paper covers only a subset of the predicted pathway (oxidative stress in fibroblasts), not the full EGFR/ALK/AXL or MMP signalling proposed by the network analysis.

As the authors state, these findings 'provide a scientific foundation for the design of clinical trials' rather than demonstrating clinical efficacy; no periodontal outcome in humans has yet been tested.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology